Lipidor AB
STO:LIPI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (52.9), the stock would be worth kr-0.9 (518% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -12.7 | kr0.22 |
0%
|
| Industry Average | 52.9 | kr-0.9 |
-518%
|
| Country Average | 23.9 | kr-0.41 |
-289%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| SE |
L
|
Lipidor AB
STO:LIPI
|
174.9m SEK | -12.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 44.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.4 |
| Median | 23.9 |
| 70th Percentile | 32.1 |
| Max | 8 163.4 |
Other Multiples
Lipidor AB
Glance View
Lipidor AB is a drug development company. The company is headquartered in Danderyd, Stockholm. The company went IPO on 2019-09-27. The firm is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The firm develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Company’s cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.
